Progress on Antiangiogenic Therapy for Patients with Malignant Glioma

Table 1

Examples of antiangiogenic agents in clinical trial for patients with high grade glioma.

Drug	Type	Targets
ABT-510	Thrombospondin-1 mimetic peptide	CD36 receptor
AMG 102	Monoclonal antibody	HGF/SF
Aflibercept	Soluble decoy receptor	VEGF-A,B, PlGF
Bevacizumab	Monoclonal antibody	VEGF-A
Brivanib	Tyrosine kinase inhibitor	FGFR, VEGFR2
Cediranib	Tyrosine kinase inhibitor	VEGFR1–3, PDGFRβ, c-Kit
Cilengitide	RGD synthetic peptide	Integrins αvβ3, αvβ5
CT-322	Fibronectin (adnectin)-based inhibitor	VEGFR1–3
Dasatinib	Tyrosine kinase inhibitor	PDGFRβ, Src, BCR-ABL, c-Kit, EphA2
Imatinib	Tyrosine kinase inhibitor	PDGFRβ, BCR-ABL, c-Kit
Lenalidomide	Immunomodulatory and anti-inflammatory	FGF pathway
Pazopanib (GW786034)	Tyrosine kinase inhibitor	VEGFR1–3, PDGFRβ, c-Kit
Sorafenib	Tyrosine kinase inhibitor	VEGFR2,3, BRAF, PDGFRβ, c-Kit, Ras, p38α
Sunitinib	Tyrosine kinase inhibitor	VEGFR2, PDGFRβ, Flt3, c-Kit
Tandutinib (MLN518)	Tyrosine kinase inhibitor	PDGFRβ, Flt3, c-Kit
Vandetanib (ZD6474)	Tyrosine kinase inhibitor	VEGFR2, EGFR, RET
Vatalanib (PTK787)	Tyrosine kinase inhibitor	VEGFR1–3, PDGFRβ, c-Kit
XL-184	Tyrosine kinase inhibitor	VEGFR2, Met, RET, c-Kit, Flt3, Tie-2

A more complete listing of anti-angiogenic agents in clinical trials for patients with high grade gliomas can be found at the National Institutes of Health website http://www.clinicaltrials.gov/ when searching for “glioma, brain cancer, glioblastoma, and angiogenesis”.